Pay in 4 interest-free payments of $7.29 Learn more
Ships within 48 hours · Estimated delivery Oct 4 - Oct 9
Triple-hormone-receptor agonist Retatrutide for obesity: Phase 2 trial (48-week study, up to 24% weight loss) American Diabetes Association (2023) ADA Press Release: Novel agent Retatrutide results in substantial weight reduction (83rd Scientific Sessions, Phase 2 data) ADA Meeting News (2023) Phase 2 trial results: benefits of Retatrutide in obesity, type 2 diabetes, NASH (83rd ADA Scientific Sessions coverage) ClinicalTrials.gov Study of Retatrutide (LY3437943) in adults with obesity (NCT04881760
Researchers should ensure all handling complies with relevant laboratory guidelines
Erratum in: Med Sci Sports Exerc
Based on current clinical evidence, tirzepatide (Zepbound) produces the highest average weight loss, followed by semaglutide (Wegovy), and then liraglutide (Saxenda)
This is how many people are still able to lose weight while enjoying some of their favorite foods
